PURPOSE: To assess the diagnostic value of fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in screening for melanoma metastases. MATERIAL AND METHODS: The case records of 94 melanoma patients who had been examined by whole-body FDG-PET between 1995 and 1999 were evaluated retrospectively. Forty patients showed evidence of lymphogenous and 42 of hematogenous metastasis. The maximal interval between PET and the diagnostic procedure under comparison was 2 weeks. Confirmation of the findings was based on histology or the clinical or radiological course. RESULTS: In 24 patients, all diagnostic examinations including CT had been performed within 2 weeks from PET. In no case did PET change the staging. In 13 patients, PET agreed with morphological diagnosis in the number of metastatically invaded organs. This included 3 patients without metastases. The estimated number of organs invaded by metastases was higher with PET in 5 patients and higher with morphological imaging techniques in 6 patients. Among the PET findings with higher or equivocal counts of organs with metastases there were 2 confirmed false-positive findings. CONCLUSION: In a selected patient population, FDG-PET was found to be inferior to CT for diagnosing lung and liver metastases. The supplementary use of FDG-PET is not generally of value once metastasis has been established.
PURPOSE: To assess the diagnostic value of fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in screening for melanoma metastases. MATERIAL AND METHODS: The case records of 94 melanomapatients who had been examined by whole-body FDG-PET between 1995 and 1999 were evaluated retrospectively. Forty patients showed evidence of lymphogenous and 42 of hematogenous metastasis. The maximal interval between PET and the diagnostic procedure under comparison was 2 weeks. Confirmation of the findings was based on histology or the clinical or radiological course. RESULTS: In 24 patients, all diagnostic examinations including CT had been performed within 2 weeks from PET. In no case did PET change the staging. In 13 patients, PET agreed with morphological diagnosis in the number of metastatically invaded organs. This included 3 patients without metastases. The estimated number of organs invaded by metastases was higher with PET in 5 patients and higher with morphological imaging techniques in 6 patients. Among the PET findings with higher or equivocal counts of organs with metastases there were 2 confirmed false-positive findings. CONCLUSION: In a selected patient population, FDG-PET was found to be inferior to CT for diagnosing lung and liver metastases. The supplementary use of FDG-PET is not generally of value once metastasis has been established.
Authors: Felix M Mottaghy; Cord Sunderkötter; Roland Schubert; Petra Wohlfart; Norbert M Blumstein; Bernd Neumaier; Gerhard Glatting; Cueneyt Ozdemir; Andreas K Buck; Karin Scharffetter-Kochanek; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2007-02-13 Impact factor: 9.236
Authors: Thomas Pfluger; Henriette Ingrid Melzer; Vera Schneider; Christian La Fougere; Eva Coppenrath; Carola Berking; Peter Bartenstein; Mayo Weiss Journal: Eur J Nucl Med Mol Imaging Date: 2011-01-06 Impact factor: 9.236
Authors: Marius E Mayerhoefer; Helmut Prosch; Christian J Herold; Michael Weber; Georgios Karanikas Journal: Eur Radiol Date: 2012-06-01 Impact factor: 5.315
Authors: Steven E Finkelstein; Jorge A Carrasquillo; John M Hoffman; Barbara Galen; Peter Choyke; Donald E White; Steven A Rosenberg; Richard M Sherry Journal: Ann Surg Oncol Date: 2004-07-12 Impact factor: 5.344
Authors: Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams Journal: Cochrane Database Syst Rev Date: 2019-07-01